Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  8/30/2012
Clinical Research Facility
mi
from
Dallas, TX
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 8/30/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  8/30/2012
Clinical Research Facility
mi
from
Norfolk, VA
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 8/30/2012
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on a Stable Dose of Metformin
Status: Enrolling
Updated:  8/31/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on a Stable Dose of Metformin
Status: Enrolling
Updated: 8/31/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on a Stable Dose of Metformin
Status: Enrolling
Updated:  8/31/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on a Stable Dose of Metformin
Status: Enrolling
Updated: 8/31/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes
A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes
Status: Enrolling
Updated:  9/7/2012
Novo Nordisk Clinical Trial Call Center
mi
from
Atlanta, GA
A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes
A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes
Status: Enrolling
Updated: 9/7/2012
Novo Nordisk Clinical Trial Call Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluation of a Lifestyle Intervention for Employees With Prediabetes
Evaluation of a Lifestyle Intervention for Employees With Prediabetes
Status: Enrolling
Updated:  9/7/2012
Ohio State University
mi
from
Columbus, OH
Evaluation of a Lifestyle Intervention for Employees With Prediabetes
Evaluation of a Lifestyle Intervention for Employees With Prediabetes
Status: Enrolling
Updated: 9/7/2012
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria
Status: Enrolling
Updated:  9/11/2012
Pfizer Investigational Site
mi
from
Los Angeles, CA
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria
Status: Enrolling
Updated: 9/11/2012
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria
Status: Enrolling
Updated:  9/11/2012
Pfizer Investigational Site
mi
from
Atlantis, FL
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria
Status: Enrolling
Updated: 9/11/2012
Pfizer Investigational Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria
Status: Enrolling
Updated:  9/11/2012
Pfizer Investigational Site
mi
from
Detroit, MI
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria
Status: Enrolling
Updated: 9/11/2012
Pfizer Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria
Status: Enrolling
Updated:  9/11/2012
Pfizer Investigational Site
mi
from
Duluth, MN
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria
Status: Enrolling
Updated: 9/11/2012
Pfizer Investigational Site
mi
from
Duluth, MN
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria
Status: Enrolling
Updated:  9/11/2012
Pfizer Investigational Site
mi
from
Rochester, NY
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria
Status: Enrolling
Updated: 9/11/2012
Pfizer Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Nephrology Associates, P.C.
mi
from
Birmingham, AL
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Nephrology Associates, P.C.
mi
from
Birmingham, AL
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
AKDHC Sun City Nephrology
mi
from
Peoria, AZ
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
AKDHC Sun City Nephrology
mi
from
Peoria, AZ
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
AKDHC Medical Research Services, LLC
mi
from
Phoenix, AZ
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
AKDHC Medical Research Services, LLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
AKDHC Central Nephrology
mi
from
Phoenix, AZ
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
AKDHC Central Nephrology
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
AKDHC Medical Research Greenway Office
mi
from
Phoenix, AZ
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
AKDHC Medical Research Greenway Office
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Southwest Clinical Research Institute
mi
from
Tempe, AZ
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Southwest Clinical Research Institute
mi
from
Tempe, AZ
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Southern Arizona VA Healthcare System
mi
from
Tucson, AZ
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Southern Arizona VA Healthcare System
mi
from
Tucson, AZ
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Fayetteville Diagnostic Clinic, Ltd
mi
from
Fayetteville, AR
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Fayetteville Diagnostic Clinic, Ltd
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
California Institute of Renal Research
mi
from
La Mesa, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
California Institute of Renal Research
mi
from
La Mesa, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Clinical Trials of St. Jude Heritage Medical Group
mi
from
Fullerton, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Clinical Trials of St. Jude Heritage Medical Group
mi
from
Fullerton, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Marin Endocrine Care & Research Associates
mi
from
Greenbrae, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Marin Endocrine Care & Research Associates
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Scripps Clinic
mi
from
La Jolla, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Scripps Clinic
mi
from
La Jolla, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Tower Nephrology Medical Group
mi
from
Los Angeles, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Tower Nephrology Medical Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Academic Medical Research Institute
mi
from
Los Angeles, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Academic Medical Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
DaVita - Century City
mi
from
Los Angeles, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
DaVita - Century City
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
University of Southern California
mi
from
Los Angeles, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Richard Cherlin, MD
mi
from
Los Gatos, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Richard Cherlin, MD
mi
from
Los Gatos, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
La Jolla Clinical Research, Inc
mi
from
Chula Vista, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
La Jolla Clinical Research, Inc
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
The Endocrine Medical Group, Inc.
mi
from
Orange, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
The Endocrine Medical Group, Inc.
mi
from
Orange, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Nephrology Specialist Medical Group
mi
from
Orange, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Nephrology Specialist Medical Group
mi
from
Orange, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
University of California, Irvine Medical Center
mi
from
Orange, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Apex Research of Riverside
mi
from
Riverside, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Apex Research of Riverside
mi
from
Riverside, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Capital Nephrology Medical Group
mi
from
Sacramento, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Capital Nephrology Medical Group
mi
from
Sacramento, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Gopal Krishna MD
mi
from
Salinas, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Gopal Krishna MD
mi
from
Salinas, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
North America Research Institute
mi
from
Azusa, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
North America Research Institute
mi
from
Azusa, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Sansum Clinic
mi
from
Santa Barbara, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Sansum Clinic
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Stanford Nephrology Offices
mi
from
Stanford, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Stanford Nephrology Offices
mi
from
Stanford, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Infosphere Clinical Research, Inc.
mi
from
West Hills, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Infosphere Clinical Research, Inc.
mi
from
West Hills, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Whittier Internal Medicine
mi
from
Whittier, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Whittier Internal Medicine
mi
from
Whittier, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
North Valley Nephrology
mi
from
Yuba City, CA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
North Valley Nephrology
mi
from
Yuba City, CA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Western Nephrology and Metabolic Bone Disease
mi
from
Arvada, CO
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Western Nephrology and Metabolic Bone Disease
mi
from
Arvada, CO
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Denver Nephrologist, PC
mi
from
Denver, CO
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Denver Nephrologist, PC
mi
from
Denver, CO
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Nephrology & Hypertension Associates PC
mi
from
Middlebury, CT
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Nephrology & Hypertension Associates PC
mi
from
Middlebury, CT
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Gilbert M Eisner MD
mi
from
Washington,
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Gilbert M Eisner MD
mi
from
Washington,
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
George Washington University Medical Faculty Associates
mi
from
Washington,
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
George Washington University Medical Faculty Associates
mi
from
Washington,
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Gulfcoast Endocrine and Diabetes Center
mi
from
Clearwater, FL
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Gulfcoast Endocrine and Diabetes Center
mi
from
Clearwater, FL
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
East Coast Institute for Research
mi
from
Jacksonville, FL
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
East Coast Institute for Research
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Jacksonville Heart Center
mi
from
Jacksonville, FL
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Jacksonville Heart Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials